StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note issued to investors on Wednesday. The firm issued a sell rating on the stock.
Separately, Roth Mkm restated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a research note on Monday, July 8th.
View Our Latest Analysis on BPTH
Bio-Path Stock Performance
Bio-Path (NASDAQ:BPTH – Get Free Report) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the previous year, the business posted ($10.60) EPS. Equities analysts anticipate that Bio-Path will post -6.2 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent SEC filing. 5.74% of the stock is owned by hedge funds and other institutional investors.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Stories
- Five stocks we like better than Bio-Path
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is a support level?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Are the U.K. Market Holidays? How to Invest and Trade
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.